Experimental Treatments

Pharmacokinetics and Dosing of MK-0518 in Healthy Volunteers   10/10/06

New Data on MK-0518 Drug Interactions   10/10/06

Differential Effect of MK-0518 and Efavirenz on Serum Lipids Levels   10/10/06

Elvucitabine Monotherapy Demonstrates Antiviral Activity in 7-day Study   10/10/06

Darunavir/ritonavir plus TMC125 Shows Good Efficacy and Safety in Patients with Resistant HIV   10/03/06

MK-0518, Experimental Integrase Inhibitor from Merck, Shows Significant Potency in HIV Patients with Triple-class Resistant Virus   9/29/06







Google_______________



 

 

 

 



 

 

 

 

 


Conference
Main Page